- Conditions
- End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
- Interventions
- Conditioning and Stem cell infusion
- Combination Product
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 202
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Allogeneic Pancreatic Islet Cells, Antithymocyte Globulin, Sirolimus, Tacrolimus, Etanercept, Islet Transplantation, Basiliximab
- Biological · Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 7
- States / cities
- San Francisco, California • Miami, Florida • Atlanta, Georgia + 3 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Biological · Drug
- Lead sponsor
- Human Genome Sciences Inc., a GSK Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 503 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Covina, California • La Palma, California + 49 more
- Conditions
- Kidney Transplant Dysfunction
- Interventions
- Not listed
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Rheumatic Disease
- Interventions
- Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
- Drug · Biological
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- End-Stage Renal Disease
- Interventions
- Basiliximab, Cyclosporine, Tacrolimus, Sirolimus, Methylprednisolone, Prednisone, Bactrim
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day to 20 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more
- Conditions
- Devic's Disease
- Interventions
- Hematopoietic Stem Cell Transplantation, Cyclophosphamide, G-CSF, rATG, Mesna, Rituximab, Methylprednisolone
- Procedure · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Kidney Transplant, Immunology, Immunosuppression
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Kidney Transplantation
- Interventions
- Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
- Drug · Biological
- Lead sponsor
- Singulera Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota
- Conditions
- Renal Transplant
- Interventions
- Generic Tacrolimus, Branded Tacrolimus
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Philadelphia, Pennsylvania
- Conditions
- Renal Transplant Rejection
- Interventions
- Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
- Drug · Other · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Sirolimus, Tacrolimus, Mycophenolate mofetil, Mycophenolic acid
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- U.S. locations
- 3
- States / cities
- Miami, Florida • Boston, Massachusetts • St Louis, Missouri
- Conditions
- Kidney Transplant Recipients, Old Age
- Interventions
- Conversion to extended-release tacrolimus, Maintenance of immediate-release tacrolimus
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Systemic Lupus Erythematous (SLE)
- Interventions
- Solu-Medrol 1mg/kg, Solu-Medrol 250 mg
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Behavior and Behavior Mechanisms
- Interventions
- Peer Mentoring, e-Communication with mentor
- Behavioral
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 14 Years to 23 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Abdominal Wall Defect
- Interventions
- abdominal wall transplantation, Immunosuppressive Agents
- Procedure · Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Uveitis
- Interventions
- fluocinolone acetonide intraocular implant, oral corticosteroid with immunosuppressive agents as needed
- Drug
- Lead sponsor
- JHSPH Center for Clinical Trials
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 21
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Computerized patient decision-aid, Usual care (lupus pamphlet)
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
- Interventions
- Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Myeloid Malignancies, Lymphoid Malignancies
- Interventions
- NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001
- Biological
- Lead sponsor
- Cristina Gasparetto
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- Galactose
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 2 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more
- Conditions
- Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
- Interventions
- Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Prednisone, Syngeneic Bone Marrow Transplantation
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 71 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2030
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Seattle, Washington
- Conditions
- Lung Transplant
- Interventions
- Extended-Release Tacrolimus, Immediate-Release Tacrolimus
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York